Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading.Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its late-stage pipeline.Merus shares jumped 38.2% to $95.21 in the pre-market trading session.Here are some other stocks moving in pre-market trading.GainersSteakholder Foods Ltd – ADR (NASDAQ: STKH) rose 92% to $8.32 in pre-market trading. Steakholder Foods recently announced signing of agreement for the acquisition ...

MoonLake Immunotherapeutics (NASDAQ:MLTX) is one of the Best Stocks to Buy for the Next 3 Months According to Hedge Funds. On August 21, Leerink Partners analyst Thomas Smith reiterated a Buy rating on MoonLake Immunotherapeutics (NASDAQ:MLTX) with a price target of $73. Smith highlighted the potential of the company’s Sonelokimab in treating moderate-to-severe hidradenitis suppurativa. He noted that the upcoming Phase 3 VELA trial results to be a key catalyst for the stock and believes that it will show ...

ZUG, Switzerland, August 5, 2025 – MoonLake Immunotherapeutics (NASDAQ:MLTX) ("MoonLake" or the "Company"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced its financial results for the second quarter of 2025. Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, said: "Q2 has been another strong quarter for MoonLake. We narrowed guidance for the timing of the primary endpoint readout for our pivotal Phas ...

文章核心观点 - 该文章由Biotech Analysis Central制药服务负责人Terry Chrisomalis撰写，旨在推广其付费订阅服务[1] - 服务提供对多家制药公司的深度分析，月费49美元，年费399美元可享受33.5%折扣[1] - 该投资小组拥有600多篇生物技术投资文章，10多只中小盘股票模型组合及实时聊天等功能[2] 服务内容 - 提供制药公司深度分析服务，涵盖行业研究和个股研究[1] - 投资小组包含600+生物技术投资文章库，形成系统化研究资源[2] - 建立10+中小盘股票模型组合，每只股票配备深度分析报告[2] - 提供实时聊天功能和分析报告，协助医疗健康领域投资者决策[2] 商业模式 - 采用订阅制收费，月费标准定价49美元[1] - 年费模式定价399美元，较月费模式节省33.5%[1] - 目前提供两周免费试用期吸引用户[1]